Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Moderate to Severe Atopic Dermatitis
NCT05549947Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Oct 2022; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05549947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549947.